BioNTech SE’s RNA-based vaccine for malaria placed on clinical hold by FDA

BioNTech SE (NASDAQ:BNTX) said on Tuesday, that the U.S. Food and Drug Administration informed of a clinical hold on the company’s Investigational New Drug application and mid-stage trial evaluating its vaccine for prevention of P. falciparum malaria in healthy malaria-naive adults.